Corticosteroid use to mitigate transaminitisassociated decline in FVIII levels following valoctocogene roxaparvovec gene therapy clinical practice guidance

Simple item page
dc.article.end-page2094en
dc.article.start-page2086en
dc.citation.doi10.1016/J.JTHA.2025.02.042en
dc.contributor.authorB. A Konkleen
dc.contributor.authorF. A Peyvandien
dc.contributor.authorG. R Fosteren
dc.contributor.authorCédric R.J.R. Hermansen
dc.contributor.authorJohnny Mahlanguen
dc.contributor.authorE et alen
dc.date.accessioned2026-04-12T11:52:17Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn1538-7933en
dc.identifier.urihttps://hdl.handle.net/10539/48977
dc.journal.titleCorticosteroid use to mitigate transaminitisassociated decline in FVIII levels following valoctocogene roxaparvovec gene therapy clinical practice guidanceen
dc.journal.volume23en
dc.titleCorticosteroid use to mitigate transaminitisassociated decline in FVIII levels following valoctocogene roxaparvovec gene therapy clinical practice guidanceen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
563.84 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)